Author

Anne Emmanuelle Berger

IN FAILURE OF NON-OPTIMIZED ADALIMUMAB (ADA) WITH THERAPEUTIC SERUM LEVELS, A CHANGE IN BIOTHERAPY CLASS IS GREATER THAN AN INTENSIFICATION OF ADA DOSE IN PATIENTS WITH CROHN´S DISEASE AND HEMORRHAGIC RECTOCOLITIS
IN FAILURE OF NON-OPTIMIZED ADALIMUMAB (ADA) WITH THERAPEUTIC SERUM LEVELS, A CHANGE IN BIOTHERAPY CLASS IS GREATER THAN AN INTENSIFICATION OF ADA DOSE IN PATIENTS WITH CROHN´S DISEASE AND HEMORRHAGIC RECTOCOLITIS

Anne Emmanuelle Berger  et al.

EARLY DETECTION OF ANTI-DRUG-ANTIBODIES USING DRUG-TOLERANT ASSAY WITHIN THE INDUCTION PHASE AT WEEK 2 PREDICTS THE LOSS OF CLINICAL RESPONSE TO ANTI-TNF IN INFLAMMATORY BOWEL DISEASE PATIENTS
EARLY DETECTION OF ANTI-DRUG-ANTIBODIES USING DRUG-TOLERANT ASSAY WITHIN THE INDUCTION PHASE AT WEEK 2 PREDICTS THE LOSS OF CLINICAL RESPONSE TO ANTI-TNF IN INFLAMMATORY BOWEL DISEASE PATIENTS

Anne Emmanuelle Berger  et al.

Item 1 - 2 / 2
1